Last reviewed · How we verify

NRG Oncology — Portfolio Competitive Intelligence Brief

NRG Oncology pipeline: 0 marketed, 0 filed, 3 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 6 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Gonadotrophin Releasing Hormone Gonadotrophin Releasing Hormone phase 3 GnRH agonist GnRH receptor Oncology
Adjuvant Chemotherapy + Ovarian Function Suppression Adjuvant Chemotherapy + Ovarian Function Suppression phase 3 Combination regimen (chemotherapy + endocrine therapy) Oncology
Ovarian Function Suppression + Aromatase Inhibitor Ovarian Function Suppression + Aromatase Inhibitor phase 3 Combination endocrine therapy (GnRH agonist/antagonist + aromatase inhibitor) GnRH receptor (ovarian suppression component) and aromatase enzyme (AI component) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Abbott · 1 shared drug class
  3. Asan Medical Center · 1 shared drug class
  4. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  5. Bayer · 1 shared drug class
  6. Bristol-Myers Squibb · 1 shared drug class
  7. Centre Oscar Lambret · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NRG Oncology:

Cite this brief

Drug Landscape (2026). NRG Oncology — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nrg-oncology. Accessed 2026-05-16.

Related